EFFECTIVENESS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC HEART FAILURE

Лядова Т.І.; Вовк К.В.; Власенко О.О.; Шерстюк Л.Л.; Кратенко Г.С.; Мартиненко М.В.

doi:10.31435/rsglobal_ws/30032023/7957

Лядова Т.І. д.мед.н., Харківський національний університет імені В.Н. Каразіна, Україна, м. Харків
Вовк К.В. к.мед.н., Харківський національний університет імені В.Н. Каразіна, Україна, м. Харків
Власенко О.О. к.мед.н, Харківський національний університет імені В.Н. Каразіна, Україна, м. Харків
Шерстюк Л.Л. к.мед.н., Харківський національний університет імені В.Н. Каразіна, Україна, м. Харків
Кратенко Г.С. к.мед.н., Харківський національний університет імені В.Н. Каразіна, Україна, м. Харків
Мартиненко М.В. ас., Харківський національний університет імені В.Н. Каразіна, Україна, м. Харків

DOI: https://doi.org/10.31435/rsglobal_ws/30032023/7957

Keywords: Chronic Heart Failure, Low Left Ventricular Ejection Fraction, Dapagliflozin

Abstract

СHF is a chronic progressive disease. Today in the world there are approximately 64 million patients with CHF. The disease is associated with significant morbidity and mortality. CHF is the leading cause of hospital admissions among people over 65 years of age, placing a significant burden on the health care system and economic burden. Experts identify several main categories of heart failure, using the LVEF assessment as an indicator of heart contractility: heart failure with low EF (LVEF ≤ 40%), HF with moderately reduced EF (LVEF 41-49%) and HF with preserved EF (LVEF ≥ 50%). Approximately half of all patients with CHF have HFrEF or HFpEF, a population of patients for whom a limited set of therapeutic options are currently available. Тhanks to effect on prognosis and symptoms in patients with CHF with low EF (LVEF ≤ 40%), a favorable safety profile and ease of use (reception 1 time / day and no dose titration necessary), dapagliflozin may be considered as an addition to the standard therapy to reduce the severity of symptoms, improve the prognosis of survival incidence and reduction in the number of future hospitalizations in connection with CHF.

References

Di Angelantonio E, Kaptoge S, Wormser D, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52-60. doi: https://doi.org/10.1001/jama.2015.7008.

Sarwar N, Gao P, Kondapally Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375: 2215-22. https://doi.org/10.1016/S0140-6736(10)60484-9.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016;18(8):891-975. doi:10.1093/eurheartj/ehw128.

Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20:853-872. https://doi.org/10.1002/ejhf.1170.

Verma S. Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits. Am J Cardiol. 2019;124 Suppl 1:S36-S44. https://doi.org/10.1016/j.amjcard.2019.10.028.

Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108-2117. https://doi.org/10.1007/s00125-018-4670-7.

Gormsen LC, Svart M, Thomsen HH, et al. Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study. J Am Heart Assoc. 2017 6:e005066. https://doi.org/10.1161/JAHA.116.005066.

Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73:1931-44. https://doi.org/10.1016/j.jacc.2019.01.056.

Kappel BA, Lehrke M, Schutt K, et al. Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease. Circulation. 2017;136:969–72. https://doi.org/10.1161/CIRCULATIONAHA.117.029166.

DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11-26. https://doi.org/10.1038/nrneph.2016.170.

Karmazyn M, Gan XT, Humphreys RA, et al. The Myocardial Na+-H+ Exchange. Circulation Research. 1999;85(9):777-786. https://doi.org/10.1161/01.RES.85.9.777.

Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78-89. https://doi.org/10.1177/1479164114561992.

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377(7):644-57. https://doi.org/10.1056/NEJMoa1611925.

McMurray JJV, DeMets DL, Inzucchi SE, et al. The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics. European Journal of Heart Failure. 2019;21(11). doi:10.1002/ejhf.1548

McMurray JJV, Solomon S, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. Mass Medical Soc. 2019;381(21):1995- 2008. doi:10.1056/NEJMoa1911303.

Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF Trial. Circulation. 2019; 141:90-9. doi:10.1161/CIRCULATIONAHA.119.044138.

Furtado RHM, Bonaca MP, Raz I, et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes and prior myocardial infarction: a sub-analysis from DECLARE TIMI-58 trial. Circulation. 2019;139:2516–27. https://doi.org/10.1161/CIRCULATIONAHA.119.039996

Adamson C, Kondo T, Jhund PS, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J 2022;43:4406-17

Solomon SD, McMurray JJV, Claggett B, et al., on behalf of the DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022;387:1089-98.

Editorial: Margulies KB. DELIVERing Progress in Heart Failure With Preserved Ejection Fraction. N Engl J Med 2022;387:1138-40

Butt JH, Jhund PS, Belohlávek J, et al. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation 2022;146:1210-24.